一分钟看懂
这是一项关于Squamous Cell Carcinoma of the Penis, Usual Type的III 期研究，登记的药物或干预包括ILND - Inguinal Lymph Node Dissection；Paclitaxel；Ifosfamide；Cisplatin；Intensity modulated radiation treatment (IMRT)；Prophylactic PLND - pel，当前状态为研究进行中，已停止招募。登记地点显示中国Los Angeles、Tampa、Atlanta、Chicago等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
ILND - Inguinal Lymph Node Dissection；Paclitaxel；Ifosfamide；Cisplatin；Intensity modulated radiation treatment (IMRT)；Prophylactic PLND - pelvic lymph node dissection · III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Los Angeles County-USC Medical Center · Los Angeles
- USC / Norris Comprehensive Cancer Center · Los Angeles
- Moffitt Cancer Center · Tampa
- Grady Health System · Atlanta
- Emory University Hospital/Winship Cancer Institute · Atlanta
- University of Chicago Comprehensive Cancer Center · Chicago
- Mayo Clinic · Rochester
- Ohio State University Comprehensive Cancer Center · Columbus
- University of Oklahoma Health Sciences Center · Oklahoma City
- Fox Chase Cancer Center · Philadelphia
- University of Texas M.D. Anderson Cancer Center · Houston
- Velindre NHS Trust · Cardiff
- University Hospitals of Leicester NHS Trust · Leicester
- The Royal Marsden NHS Foundation Trust · London
- St George's Hospital NHS Foundation Trust · London
- Norfolk and Norwich University Hospitals NHS Foundation Trust · Norwich
- Swansea Bay University Health Board · Swansea
公开的入选条件
- 1. Written informed consent
- 2. Measurable disease as determined by RECIST (version 1.1) criteria;
- 3. Histologically-proven squamous cell carcinoma of the penis,
- 4. Stage:
- any T, N1 (i.e. a palpable mobile unilateral inguinal lymph node), M0 or;
- any T, N2 (i.e. palpable mobile multiple or bilateral inguinal lymph nodes), M0 or;
- any T, N3 (i.e. fixed inguinal nodal mass or any pelvic lymphadenopathy), M0
- 5. Performance Status ECOG 0, 1 or 2.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT02305654；登记信息更新于 2026-08-31。